Safety of arylsulfatase A overexpression for gene therapy of metachromatic leukodystrophy

A. Capotondo, M. Cesani, S. Pepe, S. Fasano, S. Gregori, L. Tononi, M. A. Venneri, R. Brambilla, A. Quattrini, A. Ballabio, M. P. Cosma, Luigi Naldini, Alessandra Biffi

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Successful gene therapy approaches for metachromatic leukodystrophy (MLD), based either on hematopoietic stem/progenitor cells (HSPCs) or direct central nervous system (CNS) gene transfer, highlighted a requirement for high levels of arylsulfatase A (ARSA) expression to achieve correction of disease manifestations in the mouse model. Full assessment of the safety of ARSA expression above physiological levels thus represents a prerequisite for clinical translation of these approaches. Here, using lentiviral vectors (LVs), we generated two relevant models for the stringent evaluation of the consequences of ARSA overexpression in transduced cells. We first demonstrated that ARSA overexpression in human HSPCs does not affect their clonogenic and multilineage differentiation capacities in clonogenic assays and in a neonatal hematochimeric mouse model. Further, we studied ARSA overexpression in all body tissues by generating transgenic mice overexpressing the ARSA enzyme by LV up to 15-fold above the normal range and carrying multiple copies of LV in their genome. Characterization of these mice demonstrated the safety of ARSA overexpression in two main gene therapy targets, HSPCs and neurons, with maintenance of the complex functions of the hematopoietic and nervous system in the presence of supraphysiological enzyme levels. The activity of other sulfatases dependent on the same common activator, sulfatase-modifying factor-1 (SUMF1), was tested in ARSA-overexpressing HSPCs and in transgenic mice, excluding the occurrence of saturation phenomena. Overall, these data indicate that from the perspective of clinical translation, therapeutic levels of ARSA overexpression can be safely achieved. Further, they demonstrate an experimental platform for the preclinical assessment of the safety of new gene therapy approaches.

Original languageEnglish
Pages (from-to)821-836
Number of pages16
JournalHuman Gene Therapy
Volume18
Issue number9
DOIs
Publication statusPublished - Sep 2007

Fingerprint

Cerebroside-Sulfatase
Metachromatic Leukodystrophy
Genetic Therapy
Hematopoietic Stem Cells
Safety
Sulfatases
Transgenic Mice
Hematopoietic System
Enzymes
Nervous System
Reference Values
Central Nervous System
Maintenance
Genome

ASJC Scopus subject areas

  • Genetics

Cite this

Safety of arylsulfatase A overexpression for gene therapy of metachromatic leukodystrophy. / Capotondo, A.; Cesani, M.; Pepe, S.; Fasano, S.; Gregori, S.; Tononi, L.; Venneri, M. A.; Brambilla, R.; Quattrini, A.; Ballabio, A.; Cosma, M. P.; Naldini, Luigi; Biffi, Alessandra.

In: Human Gene Therapy, Vol. 18, No. 9, 09.2007, p. 821-836.

Research output: Contribution to journalArticle

Capotondo, A, Cesani, M, Pepe, S, Fasano, S, Gregori, S, Tononi, L, Venneri, MA, Brambilla, R, Quattrini, A, Ballabio, A, Cosma, MP, Naldini, L & Biffi, A 2007, 'Safety of arylsulfatase A overexpression for gene therapy of metachromatic leukodystrophy', Human Gene Therapy, vol. 18, no. 9, pp. 821-836. https://doi.org/10.1089/hum.2007.048
Capotondo, A. ; Cesani, M. ; Pepe, S. ; Fasano, S. ; Gregori, S. ; Tononi, L. ; Venneri, M. A. ; Brambilla, R. ; Quattrini, A. ; Ballabio, A. ; Cosma, M. P. ; Naldini, Luigi ; Biffi, Alessandra. / Safety of arylsulfatase A overexpression for gene therapy of metachromatic leukodystrophy. In: Human Gene Therapy. 2007 ; Vol. 18, No. 9. pp. 821-836.
@article{8aab0a72a03d4aa5bf84570f89054400,
title = "Safety of arylsulfatase A overexpression for gene therapy of metachromatic leukodystrophy",
abstract = "Successful gene therapy approaches for metachromatic leukodystrophy (MLD), based either on hematopoietic stem/progenitor cells (HSPCs) or direct central nervous system (CNS) gene transfer, highlighted a requirement for high levels of arylsulfatase A (ARSA) expression to achieve correction of disease manifestations in the mouse model. Full assessment of the safety of ARSA expression above physiological levels thus represents a prerequisite for clinical translation of these approaches. Here, using lentiviral vectors (LVs), we generated two relevant models for the stringent evaluation of the consequences of ARSA overexpression in transduced cells. We first demonstrated that ARSA overexpression in human HSPCs does not affect their clonogenic and multilineage differentiation capacities in clonogenic assays and in a neonatal hematochimeric mouse model. Further, we studied ARSA overexpression in all body tissues by generating transgenic mice overexpressing the ARSA enzyme by LV up to 15-fold above the normal range and carrying multiple copies of LV in their genome. Characterization of these mice demonstrated the safety of ARSA overexpression in two main gene therapy targets, HSPCs and neurons, with maintenance of the complex functions of the hematopoietic and nervous system in the presence of supraphysiological enzyme levels. The activity of other sulfatases dependent on the same common activator, sulfatase-modifying factor-1 (SUMF1), was tested in ARSA-overexpressing HSPCs and in transgenic mice, excluding the occurrence of saturation phenomena. Overall, these data indicate that from the perspective of clinical translation, therapeutic levels of ARSA overexpression can be safely achieved. Further, they demonstrate an experimental platform for the preclinical assessment of the safety of new gene therapy approaches.",
author = "A. Capotondo and M. Cesani and S. Pepe and S. Fasano and S. Gregori and L. Tononi and Venneri, {M. A.} and R. Brambilla and A. Quattrini and A. Ballabio and Cosma, {M. P.} and Luigi Naldini and Alessandra Biffi",
year = "2007",
month = "9",
doi = "10.1089/hum.2007.048",
language = "English",
volume = "18",
pages = "821--836",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "9",

}

TY - JOUR

T1 - Safety of arylsulfatase A overexpression for gene therapy of metachromatic leukodystrophy

AU - Capotondo, A.

AU - Cesani, M.

AU - Pepe, S.

AU - Fasano, S.

AU - Gregori, S.

AU - Tononi, L.

AU - Venneri, M. A.

AU - Brambilla, R.

AU - Quattrini, A.

AU - Ballabio, A.

AU - Cosma, M. P.

AU - Naldini, Luigi

AU - Biffi, Alessandra

PY - 2007/9

Y1 - 2007/9

N2 - Successful gene therapy approaches for metachromatic leukodystrophy (MLD), based either on hematopoietic stem/progenitor cells (HSPCs) or direct central nervous system (CNS) gene transfer, highlighted a requirement for high levels of arylsulfatase A (ARSA) expression to achieve correction of disease manifestations in the mouse model. Full assessment of the safety of ARSA expression above physiological levels thus represents a prerequisite for clinical translation of these approaches. Here, using lentiviral vectors (LVs), we generated two relevant models for the stringent evaluation of the consequences of ARSA overexpression in transduced cells. We first demonstrated that ARSA overexpression in human HSPCs does not affect their clonogenic and multilineage differentiation capacities in clonogenic assays and in a neonatal hematochimeric mouse model. Further, we studied ARSA overexpression in all body tissues by generating transgenic mice overexpressing the ARSA enzyme by LV up to 15-fold above the normal range and carrying multiple copies of LV in their genome. Characterization of these mice demonstrated the safety of ARSA overexpression in two main gene therapy targets, HSPCs and neurons, with maintenance of the complex functions of the hematopoietic and nervous system in the presence of supraphysiological enzyme levels. The activity of other sulfatases dependent on the same common activator, sulfatase-modifying factor-1 (SUMF1), was tested in ARSA-overexpressing HSPCs and in transgenic mice, excluding the occurrence of saturation phenomena. Overall, these data indicate that from the perspective of clinical translation, therapeutic levels of ARSA overexpression can be safely achieved. Further, they demonstrate an experimental platform for the preclinical assessment of the safety of new gene therapy approaches.

AB - Successful gene therapy approaches for metachromatic leukodystrophy (MLD), based either on hematopoietic stem/progenitor cells (HSPCs) or direct central nervous system (CNS) gene transfer, highlighted a requirement for high levels of arylsulfatase A (ARSA) expression to achieve correction of disease manifestations in the mouse model. Full assessment of the safety of ARSA expression above physiological levels thus represents a prerequisite for clinical translation of these approaches. Here, using lentiviral vectors (LVs), we generated two relevant models for the stringent evaluation of the consequences of ARSA overexpression in transduced cells. We first demonstrated that ARSA overexpression in human HSPCs does not affect their clonogenic and multilineage differentiation capacities in clonogenic assays and in a neonatal hematochimeric mouse model. Further, we studied ARSA overexpression in all body tissues by generating transgenic mice overexpressing the ARSA enzyme by LV up to 15-fold above the normal range and carrying multiple copies of LV in their genome. Characterization of these mice demonstrated the safety of ARSA overexpression in two main gene therapy targets, HSPCs and neurons, with maintenance of the complex functions of the hematopoietic and nervous system in the presence of supraphysiological enzyme levels. The activity of other sulfatases dependent on the same common activator, sulfatase-modifying factor-1 (SUMF1), was tested in ARSA-overexpressing HSPCs and in transgenic mice, excluding the occurrence of saturation phenomena. Overall, these data indicate that from the perspective of clinical translation, therapeutic levels of ARSA overexpression can be safely achieved. Further, they demonstrate an experimental platform for the preclinical assessment of the safety of new gene therapy approaches.

UR - http://www.scopus.com/inward/record.url?scp=34848831198&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34848831198&partnerID=8YFLogxK

U2 - 10.1089/hum.2007.048

DO - 10.1089/hum.2007.048

M3 - Article

VL - 18

SP - 821

EP - 836

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 9

ER -